Sonelokimab

索洛奇单抗

Report date: 2026/05/07 20:00:36

Base Information

Drug NameSonelokimab
Drug Alias NameAnti-IL-17A/F NanobodysonelokinabNanobody® IL-17 A/F inhibitorM-1095ALX-0761 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionInterleukin-17F inhibitorsInterleukin 17A inhibitors
TargetsInterleukin-17FInterleukin 17A
Therapy Area/IndicationsPsoriasisArthritis, PsoriaticHidradenitis Suppurativa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[26] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesMoonLake Immunotherapeutics AG
Inactive CompaniesMerck KGaA, Darmstadt, GermanyBond Avillion 2 Development Lp
Active IndicationsArthritis, PsoriaticHidradenitis Suppurativa
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A